Yvonne Koh, Ph.D.

Yvonne is an Associate at Lightstone Singapore Pte Ltd where she supports the team in evaluating and driving venture investment opportunities in the biopharmaceutical and medical device sectors.

Prior to Lightstone, she was Deputy Director at the National Research Foundation, a division of the Prime Minister’s Office Singapore, where she led the formulation of innovation policy, implemented innovation grants and managed various technology translation platforms in the life sciences sector. Yvonne was also the Vice-President of Biotech Connection Singapore, where she worked closely with innovators, community leaders, academics and investors in shaping a vibrant life sciences startup ecosystem in Singapore.

Yvonne holds a Ph.D. in Biochemistry from the University of Wisconsin, Madison and a B.Sc. from the University of Illinois, Urbana Champaign. She was a recipient of the National Science Scholarship from the Agency for Science, Technology and Research (A*STAR) Singapore.

Wen Qi Ho, Ph.D.

Wen Qi is a Vice President at Lightstone Singapore Pte,Ltd., where she evaluates new investment opportunities in the biopharmaceutical and medical device sectors out of the firm’s Singapore office.

Wen Qi attained her B.Sc. in Molecular and Cellular Biology at Johns Hopkins University, and her PhD in Immunology at Stanford University under the guidance of Professor Gerald Crabtree, a Howard Hughes Medical Institutes investigator. She was also the recipient of the National Science Scholarship from the Agency for Science, Technology and Research (A*STAR) Singapore. While at Stanford, she enrolled in the Program in Innovation and Entrepreneurship at the Stanford School of Business where she learned business fundamentals and had hands-on experience at developing an idea to business plan. Since moving to Singapore, Wen Qi has been actively involved in the Executive Committee of Biotech Connection Singapore, which aims to promote the life science entrepreneurship eco-system in Singapore by providing a platform for innovators, academics, and investors to come together.

Kenneth D. Noonan, Ph.D.

Ken is currently the CEO of Lightstone Singapore Pte, Ltd.

Previously Ken was a consultant to the life science industry. Most recently he was a senior partner and head of the European Life Sciences Practice at L.E.K. Consulting LLP. Prior to that he was a partner in the pharmaceutical practice at Booz-Allen & Hamiliton. Ken was also the founding partner and head of the European practice at The Wilkerson Group Ltd. Ken’s operating experience in discovery includes management roles at Cooper Life Sciences (to include Technicon), Becton Dickinson and Bethesda Research Labs.

Ken has served as a Board member of both public and private life science companies in Europe and the U.S. to include Intercept Pharmaceuticals Inc., Kailos Genetics and Orchid Biosciences.

During his academic career Ken authored more than 50 articles on the role of the cell surface in cell division.